Na Li1, Liwen Wei1,2, Xiaoyu Liu1, Hongjun Bai3, Yvonne Ye3, Dan Li3,4, Nan Li3, Ulrich Baxa5, Qun Wang4, Ling Lv6, Yun Chen7, Mingqian Feng2, Byungkook Lee3, Wei Gao1, Mitchell Ho3. 1. Key Laboratory of Human Functional Genomics of Jiangsu Province, National Health Commission Key Laboratory of Antibody Techniques, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu, China. 2. Bio-medical Center, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, Hubei, China. 3. Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. 4. School of Life Sciences, East China Normal University, Shanghai, China. 5. Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD. 6. Liver Transplantation Center of the First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China. 7. School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu, China.
Abstract
Wnt signaling is one of the key regulators of hepatocellular carcinoma (HCC) tumor progression. In addition to the classical receptor frizzled (FZD), various coreceptors including heparan sulfate proteoglycans (HSPGs) are involved in Wnt activation. Glypican-3 (GPC3) is an HSPG that is overexpressed in HCC and functions as a Wnt coreceptor that modulates HCC cell proliferation. These features make GPC3 an attractive target for liver cancer therapy. However, the precise interaction of GPC3 and Wnt and how GPC3, Wnt, and FZD cooperate with each other are poorly understood. In this study, we established a structural model of GPC3 containing a putative FZD-like cysteine-rich domain at its N-terminal lobe. We found that F41 and its surrounding residues in GPC3 formed a Wnt-binding groove that interacted with the middle region located between the lipid thumb domain and the index finger domain of Wnt3a. Mutating residues in this groove significantly inhibited Wnt3a binding, β-catenin activation, and the transcriptional activation of Wnt-dependent genes. In contrast with the heparan sulfate chains, the Wnt-binding groove that we identified in the protein core of GPC3 seemed to promote Wnt signaling in conditions when FZD was not abundant. Specifically, blocking this domain using an antibody inhibited Wnt activation. In HCC cells, mutating residue F41 on GPC3 inhibited activation of β-catenin in vitro and reduced xenograft tumor growth in nude mice compared with cells expressing wild-type GPC3. Conclusion: Our investigation demonstrates a detailed interaction of GPC3 and Wnt3a, reveals the precise mechanism of GPC3 acting as a Wnt coreceptor, and provides a potential target site on GPC3 for Wnt blocking and HCC therapy.
Wnt signaling is one of the key regulators of hepatocellular carcinoma (HCC) tumor progression. In addition to the classical receptor frizzled (FZD), various coreceptors including heparan sulfate proteoglycans (HSPGs) are involved in Wnt activation. Glypican-3 (GPC3) is an HSPG that is overexpressed in HCC and functions as a Wnt coreceptor that modulates HCC cell proliferation. These features make GPC3 an attractive target for liver cancer therapy. However, the precise interaction of GPC3 and Wnt and how GPC3, Wnt, and FZD cooperate with each other are poorly understood. In this study, we established a structural model of GPC3 containing a putative FZD-like cysteine-rich domain at its N-terminal lobe. We found that F41 and its surrounding residues in GPC3 formed a Wnt-binding groove that interacted with the middle region located between the lipid thumb domain and the index finger domain of Wnt3a. Mutating residues in this groove significantly inhibited Wnt3a binding, β-catenin activation, and the transcriptional activation of Wnt-dependent genes. In contrast with the heparan sulfate chains, the Wnt-binding groove that we identified in the protein core of GPC3 seemed to promote Wnt signaling in conditions when FZD was not abundant. Specifically, blocking this domain using an antibody inhibited Wnt activation. In HCC cells, mutating residue F41 on GPC3 inhibited activation of β-catenin in vitro and reduced xenograft tumor growth in nude mice compared with cells expressing wild-type GPC3. Conclusion: Our investigation demonstrates a detailed interaction of GPC3 and Wnt3a, reveals the precise mechanism of GPC3 acting as a Wnt coreceptor, and provides a potential target site on GPC3 for Wnt blocking and HCC therapy.
Authors: Robert J Kreitman; Martin S Tallman; Tadeusz Robak; Steven Coutre; Wyndham H Wilson; Maryalice Stetler-Stevenson; David J Fitzgerald; Robert Lechleider; Ira Pastan Journal: J Clin Oncol Date: 2012-02-21 Impact factor: 44.544
Authors: Andrew X Zhu; Philip J Gold; Anthony B El-Khoueiry; Thomas A Abrams; Hideo Morikawa; Norihisa Ohishi; Toshihiko Ohtomo; Philip A Philip Journal: Clin Cancer Res Date: 2013-01-29 Impact factor: 12.531
Authors: A Bengochea; M M de Souza; L Lefrançois; E Le Roux; O Galy; I Chemin; M Kim; J R Wands; C Trepo; P Hainaut; J-Y Scoazec; L Vitvitski; P Merle Journal: Br J Cancer Date: 2008-06-24 Impact factor: 7.640
Authors: Dan Li; Nan Li; Yi-Fan Zhang; Haiying Fu; Mingqian Feng; Dina Schneider; Ling Su; Xiaolin Wu; Jing Zhou; Sean Mackay; Josh Kramer; Zhijian Duan; Hongjia Yang; Aarti Kolluri; Alissa M Hummer; Madeline B Torres; Hu Zhu; Matthew D Hall; Xiaoling Luo; Jinqiu Chen; Qun Wang; Daniel Abate-Daga; Boro Dropublic; Stephen M Hewitt; Rimas J Orentas; Tim F Greten; Mitchell Ho Journal: Gastroenterology Date: 2020-02-12 Impact factor: 22.682
Authors: Sandeep Gopal; Samantha Arokiasamy; Csilla Pataki; James R Whiteford; John R Couchman Journal: Open Biol Date: 2021-02-10 Impact factor: 6.411
Authors: Bryan D Fleming; Daniel J Urban; Matthew D Hall; Thomas Longerich; Tim F Greten; Ira Pastan; Mitchell Ho Journal: Hepatology Date: 2020-01-27 Impact factor: 17.298